Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Wai Chun Bio-Technology Ltd. ( (HK:0660) ).
Wai Chun Bio-Technology Limited has disclosed that the High Court of Hong Kong has issued a judgment ordering the company and Wai Chun Group Holdings Limited to pay Island Sky Limited about HK$2.67 million, plus interest and legal costs, in relation to mesne profits, rent, rates and associated charges for office premises in Admiralty for a period between September 2022 and April 2023. The board contends that the mesne profits claimed are excessive compared with market levels, has already filed a notice of appeal, and is seeking further legal advice on possible actions such as applying for a stay of execution and submitting additional evidence, while pledging to update shareholders and investors on material developments.
More about Wai Chun Bio-Technology Ltd.
Wai Chun Bio-Technology Limited is a Hong Kong-listed company incorporated in the Cayman Islands and traded on the Main Board of the Stock Exchange of Hong Kong. The group operates under the wider Wai Chun corporate umbrella, with its governance led by chairman and chief executive officer Lam Ka Chun and supported by a board that includes three independent non-executive directors.
Average Trading Volume: 147,145
Technical Sentiment Signal: Buy
Current Market Cap: HK$49.97M
See more data about 0660 stock on TipRanks’ Stock Analysis page.